Clinical Trial Detail

NCT ID NCT03976375
Title Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-squamous non-small cell carcinoma

lung squamous cell carcinoma

Therapies

Lenvatinib

Lenvatinib + Pembrolizumab

Docetaxel

Age Groups: adult senior

No variant requirements are available.